Developmental Therapeutics
RESEARCH PROGRAM

Friday, March 16, 2018
1:00 PM – 2:00 PM
SHM I-304

“Repurposing an Antimalarial as an Anticancer Drug”

Peter Karuso
Professor of Chemistry
Macquarie University, Sydney, Australia

Lunch will be provided.
Yale Cancer Center offers biostatistics and bioinformatics support to all members/projects through the Biostatistics Shared Resource (BSR), which is led by Dr. Shuangge (Steven) Ma. Dr. Ma has over ten years of experience conducting cancer biostatistical research, including serving as co-director of the Biostatistics and Bioinformatics Core of the Yale SPORE in Skin Cancer, and is also the senior genetic statistician for the VA CT Healthcare System. YCC members are eligible to receive up to 16 hours per year of service at no cost. As funding agencies and journals continue to place increasing emphasis on proper analytics, it is critical to involve statisticians early on and in all stages of your study. Whenever you have a new project or idea, Dr. Ma urges you to contact him (shuangge.ma@yale.edu) and he will introduce you to the appropriate faculty or staff at the BSR so that you can take advantage of their expertise and your YCC member benefit.

The BSR is happy to re-announce its drop-in consultation service. Dr. Wei Wei, an experienced statistician with special expertise in clinical trial design and analysis and general analytics, provides on-site biostatistics support. Drs. Yong Kong and Ying Zhu, both with extensive experience in the analysis of genetic, genomic, proteomic, and epigenetic data, provide bioinformatics support.

**Biostatistics Shared Resource (BSR) Drop-In Office Hours - WWW213**

**Biostatistics**
Dr. Wei Wei  
Thursdays - 9am-1pm  
Fridays - 9am-5pm

**Bioinformatics**
Drs. Yong Kong and Ying Zhu  
Fridays - 1pm-5pm
Member Notables

Stand Up To Cancer recently announced a new Convergence Research Program, which will use artificial intelligence to investigate immunotherapies. As part of their new program, two Yale Cancer Center researchers were awarded grants. Rong Fan, PhD, a member of our Signal Transduction Research Program, will lead the project, "Single-Cell Functional Multi-Omics to Characterize and Monitor CAR T Therapy." Alessandro Santin, MD, a member of our Developmental Therapeutics Research Program, will lead, "Responders and Non-responders to Endometrial Cancers with Mismatch Repair."

Learn More >>

Jason Crawford, PhD, a member of Yale Cancer Center's Developmental Therapeutics Research Program, has been named the Maxine F. Singer '57 PhD Associate Professor of Chemistry and of Microbial Pathogenesis.
Member Notables

Steven Gore is one of the regular hosts of Yale Cancer Answers.
Member Notables

Roy Herbst - SWOG Cancer Research Leader

Yale Cancer Center Retweeted

SWOG Cancer Research @SWOG · Mar 13
Great pic of great @SWOG cancer research leaders. @DrRoyHerbstYale of @YaleCancer and Dr. Fred Hirsch of @IASLC are two of the investigators on our @LungMAP precision medicine trial testing new treatments for squamous cell lung cancer. Learn more at lung-map.org

Roy Herbst @DrRoyHerbstYale
At Tucson symposium today with Dr Fred Hirsch @IASLC and an audience of pathologists and clinicians discussing biomarkers for personalizing immune therapy @YaleCancer @YNHH. Also highlighting the lung...
Member Notables

Amer Zeidan speaking at the 2018 International Conference of the Jordanian Society of Hematology
Member Notables

Brian Shuch discusses the genetics of kidney cancer and how this can plan into treatment methods on Yale Cancer Answers.
Member Notables

Yale Cancer Center @YaleCancer · 2h
With Immunotherapy showing great promise for treating many types of cancer, we’re proud to announce the opening of the Center for Immuno-Oncology at Yale Cancer Center! yalecancercenter.org/news/article.a...

Co-Director Lieping Chen (CI) and Interim Co-Director Roy Herbst (DT)
Funding Opportunities – Comprehensive List check here: http://yalecancercenter.org/research/foa.aspx

SPORE in Lung Cancer Program Awards: Career Development Program
The Career Development Program will provide support of up to $50,000 to promising junior investigators and/or establish investigators who have not previously conducted lung cancer focused research.

Application Timeline: Letters of intent (LOI) are due no later than 5:00 PM, April 27, 2018

SPORE in Lung Cancer Program Awards: Developmental Research Program To provide seed money to investigators to support studies with a strong translational component that have the potential to evolve into, or be incorporated into, a full Yale SPORE in Lung Cancer project.

Application Timeline: Letters of intent are due no later than 5:00 PM, April 27, 2018
2018 YCC Internal Pilot Grants

These grants will support innovative basic, clinical, population, computational, prevention/control, and translational cancer research. The primary review criteria will be scientific excellence, innovation, cancer relevance, and the likelihood of the project evolving into federally funded cancer research. Members of Yale Cancer Center or faculty who have applied for membership are eligible to apply. The anticipated start date is May 1, 2018.

Projects headed by a member of Yale Cancer Center will be awarded up to $50,000. YCC Program Leaders may not apply for pilot funding. We welcome all potential areas of cancer research, recognizing the following funding priorities:

• Microbiome, including its role in carcinogenesis and modulation of cancer therapy
• Single cell analysis to understand tumor heterogeneity, microenvironment, tumor immune response
• Undruggable targets, including immunotherapeutic, novel delivery approaches, or synthetic lethal approaches
• DNA repair and therapeutics
• Metabolic dysregulation in cancer

In addition, applications that incorporate studies of underserved populations or novel data science and computational approaches will receive greater funding priority. Submission deadline is 11:59pm on April 2nd, 2018.

Grant guidelines and electronic application instructions can be obtained on Submittable (https://yalecancercenter.submittable.com/submit)

For scientific questions, please contact joann.sweasy@yale.edu. All other inquiries should be sent to christine.holmberg@yale.edu.
Upcoming Events - [https://medicine.yale.edu/cancer/patient/calendar/](https://medicine.yale.edu/cancer/patient/calendar/)

- **YCC Annual Retreat** – May 16th – West Campus Conference Center – Agenda TBD

- **YCC Grand Rounds** – Most Tuesdays – 12-1pm – 55 Park Street Auditorium – Speaker TBD – *Now viewable on Skype!* – Find out how on the calendar posting at the link above

- **Next DT Seminar is April 20th** - Speaker TBD

---

- Yale Dept of Urology Hosts: Men’s Health Symposium: *“Men’s Health Across the Lifespan”* with David Shin and Alexander Pastuszak – March 17 – 7-1pm – 2 Bridge St, Old Saybrook

- Radiobiology & Radiotherapy (RR) Research Program Seminar – March 19 – 11-12pm, SHM I-304 – Timothy Nottoli: *“Creating Mouse Models with the Yale Genome Editing Center”* and *“A DNA Repair Variant and Lupus”*

February Publications – Please note: These have not been reviewed for cancer relevance yet.

A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM, Parker T
Oncologist E publication ahead of print: (02/2018)
PM ID: 29438091

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer.
Gynecol Oncol Rep 23: 28-33 (02/2018)
PM ID: 29387776 PMC5771964

DNA Repair: Unconventional Lesions Require Unconventional Repair.
Herzon SB
Biochemistry 57: 1057-1058 (02/2018)
PM ID: 29406697
February Publications

Endothelial Cell Autonomous Role of Akt1: Regulation of Vascular Tone and Ischemia-Induced Arteriogenesis.
Arterioscler Thromb Vasc Biol E publication ahead of print: (02/2018)
PM ID: 29449333

Erythema Nodosum-like Eruption in the Setting of Sorafenib Therapy.
Coleman EL, Cowper SE, Stein SM, Leventhal JS
JAMA Dermatol E publication ahead of print: (02/2018)
PM ID: 29453869

In vitro and in vivo activity of IMGN853, an Antibody-Drug Conjugate targeting Folate Receptor Alpha linked to DM4, in biologically aggressive endometrial cancers.
Mol Cancer Ther : (02/2018)
PM ID: 29440294

Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?
Shallis RM, Zeidan AM
Leuk Lymphoma : 1-3 (02/2018)
PM ID: 29411698

/**/ - Indicate Intra- and Inter-programmatic collaboration
February Publications

Microbiota-Regulated Outcomes of Human Cancer Immunotherapy via the PD-1/PD-L1 Axis. 
Patel J, Crawford JM 
Biochemistry 57: 901-903 (02/2018) 
PM ID: 29350031

Mirror Movements in a Patient With Brain Tumor. 
Kaulen LD, Baehring JM 
JAMA Neurol E publication ahead of print: (02/2018) 
PM ID: 29435583

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. 
Shallis RM, Zeidan AM 
BMC Hematol 18: 4 (02/2018) 
PM ID: 29435332 PMC5796398

MRI-Ultrasound Fusion Targeted Biopsy of Prostate Imaging Reporting and Data System Version 2 Category 5 Lesions Found False-Positive at Multiparametric Prostate MRI. 
AJR Am J Roentgenol E publication ahead of print: W1-W8 (02/2018) 
PM ID: 29489409
February Publications

Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.

* Curtis BR, Hsu YS, Podoltsev N, Lacy J, Curtis S, Samuel MS, Zutavern K, DeSimone RA, Bougie DW, Aster RH
Blood E publication ahead of print: (02/2018)
PM ID: 29439950

The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.

J Viral Hepat E publication ahead of print: (02/2018)
PM ID: 29406608

Treatment deintensification in human papillomavirus-positive oropharynx cancer: Outcomes from the National Cancer Data Base.

** Cheraghliou S, Yu PK, Otemba MD, Park HS, Bhatia A, Zogg CK, Mehra S, Yarbrough WG, Judson BL
Cancer 124: 717-726 (02/2018)
PM ID: 29243245

Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level.

** Charkoftaki G, Rattray NJW, Andrén PE, Caprioli RM, Castellino S, Duncan MW, Goodwin RJA, Schey KL, Shahidi-Latham SK, Veselkov KA, Johnson CH, Vasiliou V
Hum Genomics 12: 10 (02/2018)
PM ID: 29482659 PMCID5828306

* - Indicates Intra-programmatic collaboration
** - Indicated Inter-programmatic collaboration
Did I miss your good news??

Email: 
christina.dreyfus@yale.edu
by March 30th for April’s seminar